The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
FDA approval of subcutaneous daratumumab, carfilzomib, and dexamethasone for R/R MM
On November 30, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of subcutaneous daratumumab (daratumumab + hyaluronidase-fihj) in combination with carfilzomib and dexamethasone (Dara-Kd) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM) with ≤3 prior lines of therapy. The decision was based on results of a single cohort of patients in the ongoing PLEIADES trial (NCT03412565).1
PLEIADES trial1,2
- A phase II, multicenter, multicohort study investigating the use of subcutaneous daratumumab in combination with standard MM treatment regimens
- Trial start date: April 26, 2018
- Primary completion date: August 12, 2020
- Estimated end date: June 7, 2022
- Enrollment in Dara-Kd cohort: adult patients with R/R MM with ≤3 prior lines of therapy (n = 66)
- Primary outcome measure: overall response rate defined as the percentage of patients who achieve partial response or better based on the International Myeloma Working Group criteria
Results1
- Overall response rate: 84.8% (95% confidence interval, 73.9–92.5%)
- With a median follow-up of 9.2 months, the median duration of response had not yet been reached
- Approximately 85.2% of patients maintained a response for ≥6 months
- 82.5% of patients maintained a response for ≥9 months
- The most common adverse reactions occurring in ≥20% of patients were upper respiratory tract infections, fatigue, insomnia, hypertension, diarrhea, cough, dyspnea, headache, pyrexia, nausea, and peripheral edema
Recommended dosing regimen1
Subcutaneous daratumumab (1,800 mg/30,000 units daratumumab/hyaluronidase) and dexamethasone are administered as per standard dosing.
The recommended dosing of carfilzomib intravenously over 30 minutes in each 28-day cycle is:
- Once weekly:
- 20 mg/m2 on Cycle 1 Day 1, and if tolerated 70 mg/m2 on Days 8 and 15
- Then 70 mg/m2 on Days 1, 8, and 15 for Cycle 2 onwards
- Or twice weekly:
- 20 mg/m2 on Cycle 1 Days 1 and 2, and if tolerated 56 mg/m2 on Days 8, 9, 15, and 16
- Then 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16 for Cycle 2 onwards
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content